Importantly, we not only confirmed that CHREBP could be a valuable prognostic marker for GC but also revealed the significance of the CHREBP/cyclin D1/Rb/E2F1 pathway in GC development, which might assist clinicians in more effectively treating GC patients. Here, E2F1 is linked to gastric cancer.